AngioDynamics: appoints Eric Honroth as CEO

What happened

• The filing says the board appointed Eric Honroth to serve as president and chief executive officer of AngioDynamics, Inc., effective Nov 2, 2026, and that the company entered into an employment agreement with Mr. Honroth on Oct 3, 2026.
• The filing says James C. Clemmer intends to retire as president and chief executive officer on the earlier of Nov 30, 2026 and the appointment of a successor, and that Mr. Clemmer entered a consulting agreement with the company on Oct 5, 2026. The filing also says Howard W. Donnelly notified the board he will retire as a director at the end of his current term.

Key details

• Mr. Honroth, age 55, will have an initial one-year term (auto-renewing unless 60 days’ notice is given), a base salary of $735,000 per year and an annual bonus target of 95% of base salary.
• Initial grants effective on the effective date: a long-term incentive award with a grant-date value of $1,487,116 (50% restricted stock units and 50% performance share units), a one-time restricted stock unit award with a grant-date value of $450,000 vesting in two equal installments on the first and second anniversaries, and a cash sign-on bonus of $350,000 (repayable if he resigns without Good Reason or is terminated for Cause before the first anniversary).
• Additional allowances and benefits: a monthly commuting and temporary living allowance of $10,000 for up to 24 months, an automobile allowance of $24,000 per year, reimbursement for business travel, and participation in senior executive benefit plans.
• Termination and change in control provisions: if terminated without Cause or he resigns for Good Reason, Mr. Honroth is entitled to continued base salary for 18 months, prior year bonus if earned, 18 months of company-paid health insurance (subject to exceptions) and continued vesting of unvested equity for 12 months (subject to performance conditions). If a change in control occurs and within 24 months he is terminated without Cause or resigns for Good Reason, he is entitled to continued base salary for 24 months, a lump sum equal to his target annual bonus, 18 months of company-paid health coverage, and immediate full vesting of outstanding unvested equity (performance awards vest at the applicable level).
• Mr. Clemmer’s consulting agreement provides a consulting fee of $30,000 per month and reimbursement of reasonable expenses during the consulting term; if the company ends the consulting term early, it will pay a lump sum for the remaining fees.
• The board approved equity retention agreements for the executive leadership team that accelerate vesting of previously issued equity grants for eligible employees under specified conditions.

Why it may matter

• The filing reports Item 1.01 (entry into a material definitive agreement—the Honroth employment agreement) and Item 5.02 (departure and appointment of certain officers and directors and related compensatory arrangements, including Clemmer’s consulting agreement, equity retention agreements and Donnelly’s retirement). This filing does not show why the insider traded or why the company acted.